Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for CACNA1C, CHRNA7 and MAPK1
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: Genetics factors are likely to play a role in the risk, clinical presentation and treatment outcome in major depressive disorder (MDD). In this study, we investigated the role of three candidate genes for MDD; calcium voltagegated channel subunit alpha1 C (CACNA1C ), cholinergic receptor nicotinic alpha 7 subunit (CHRNA7 ), and mitogenactivated protein kinase 1 (MAPK1 ). Methods: Two-hundred forty-two MDD patients and 326 healthy controls of Korean ancestry served as samples for the analyses. Thirty-nine single nucleotide polymorphisms (SNPs) within CACNA1C, CHRNA7, and MAPK1 genes were genotyped and subsequently tested for association with MDD (primary analysis) and other clinical features (symptoms’ severity, age of onset, history of suicide attempt, treatment outcome) (secondary analyses). Single SNPs, haplotypes and epistatic analyses were performed. Results: Single SNPs were not associated with disease risk and clinical features. However, a combination of alleles (haplotype) within MAPK1 was found associated with MDD-status. Secondary analyses detected a possible involvement of CACNA1C haplotype in resistance to antidepressant treatment. Conclusion: These data suggest a role for MAPK1 and CACNA1C in MDD risk and treatment resistance, respectively. However, since many limitations characterize the analysis, the results must be considered with great caution and verified.
Abstract
Objective: Genetics factors are likely to play a role in the risk, clinical presentation and treatment outcome in major depressive disorder (MDD). In this study, we investigated the role of three candidate genes for MDD; calcium voltagegated channel subunit alpha1 C (CACNA1C ), cholinergic receptor nicotinic alpha 7 subunit (CHRNA7 ), and mitogenactivated protein kinase 1 (MAPK1 ). Methods: Two-hundred forty-two MDD patients and 326 healthy controls of Korean ancestry served as samples for the analyses. Thirty-nine single nucleotide polymorphisms (SNPs) within CACNA1C, CHRNA7, and MAPK1 genes were genotyped and subsequently tested for association with MDD (primary analysis) and other clinical features (symptoms’ severity, age of onset, history of suicide attempt, treatment outcome) (secondary analyses). Single SNPs, haplotypes and epistatic analyses were performed. Results: Single SNPs were not associated with disease risk and clinical features. However, a combination of alleles (haplotype) within MAPK1 was found associated with MDD-status. Secondary analyses detected a possible involvement of CACNA1C haplotype in resistance to antidepressant treatment. Conclusion: These data suggest a role for MAPK1 and CACNA1C in MDD risk and treatment resistance, respectively. However, since many limitations characterize the analysis, the results must be considered with great caution and verified.
참고문헌 (26)
- Berrios GE, "The psychopathology of affectivity : conceptual and historical aspects", Psychol Med, 15, pp.745~758 (1985)
- Otte C, "Major depressive disorder", Nat Rev Dis Primers, 2, pp.16065~ (2016)
- Alessandro Serretti, "The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants", Clinical Psychopharmacology and Neuroscience, 16(1), pp.1~6 (2018), 대한정신약물학회[DOI]
- Jikuang Zhao, "Association of CDKN2B-AS1 rs1333049 with Brain Diseases: A Case-control Study and a Meta-analysis", Clinical Psychopharmacology and Neuroscience, 15(1), pp.53~58 (2017), 대한정신약물학회[DOI]
- Krishnan V, "Linking molecules to mood : new insight into the biology of depression", Am J Psychiatry, 167, pp.1305~1320 (2010)
- Vogelzangs N, "Association of depressive disorders, depression characteristics and antidepressant medication with inflammation", Transl Psychiatry, 2, pp.e79~ (2012)
- Zunszain PA, "Inflammation and depression", Curr Top Behav Neurosci, 14, pp.135~151 (2013)
- Rabenstein RL, "The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2-or alpha7-nicotinic acetylcholine receptor subunit knockout mice", Psychopharmacology(Berl), 189, pp.395~401 (2006)
- Shytle RD, "Nicotinic acetylcholine receptors as targets for antidepressants", Mol Psychiatry, 7, pp.525~535 (2002)
- Drago A, "The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes", Prog Neurobiol, 94, pp.418~460 (2011)
- Dedic N, "Cross-disorder risk gene CACNA1C differentially modulates susceptibility to psychiatric disorders during development and adulthood", Mol Psychiatry, 23, pp.533~543 (2018)
- Rao S, "Common variants in CACNA1C and MDD susceptibility : A comprehensive meta-analysis", Am J Med Genet B Neuropsychiatr Genet, 171, pp.896~903 (2016)
- He K, "CACNA1C, schizophrenia and major depressive disorder in the Han Chinese population", Br J Psychiatry, 204, pp.36~39 (2014)
- Berger SM, "The role of L-type voltage-gated calcium channels Cav1.2 and Cav1.3 in normal and pathological brain function", Cell Tissue Res, 357, pp.463~476 (2014)
- Levin ED, "7-Nicotinic receptors and cognition", Curr Drug Targets, 13, pp.602~606 (2012)
- Hetman M, "Role of extracellular signal regulated kinases 1 and 2 in neuronal survival", Eur J Biochem, 271, pp.2050~2055 (2004)
- Calati R, "Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients", Prog Neuropsychopharmacol Biol Psychiatry, 44, pp.271~278 (2013)
- García-Fuster MJ, "FADD adaptor and PEA-15", ERK1, Neuroscience, pp.2014, 277[DOI]
- Calabrò M, "Genes involved in neurodevelopment, neuroplasticity, and bipolar disorder : CACNA1C, CHRNA1, and MAPK1", Neuropsychobiology, 74, pp.159~168 (2016)
- Cocchi E, "Genome-wide association study of antidepressant response : involvement of the inorganic cation transmembrane transporter activity pathway", BMC Psychiatry, 16, pp.106~ (2016)
- Sheehan DV, "The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10", J Clin Psychiatry, 59(Suppl 20), pp.22~33 (1998)
- Zimmerman M, "Severity classification on the Hamilton Depression Rating Scale", J Affect Disord, 150, pp.384~388 (2013)
- Schosser A, "European Group for the Study of Resistant Depression(GSRD)--where have we gone so far : review of clinical and genetic findings", Eur Neuropsychopharmacol, 22, pp.453~468 (2012)
- Barrett JC, "Haploview : analysis and visualization of LD and haplotype maps", Bioinformatics, 21, pp.263~265 (2005)
- Rosand J, "Epistasis is coming : are we ready", Stroke, 36, pp.1879~1880 (2005)
- Benjamini Y, "Controlling the false discovery rate in behavior genetics research", Behav Brain Res, 125, pp.279~284 (2001)